External Content

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

(Bloomberg) -- South Africa joined the global crackdown on the rising cost of life-saving cancer treatments by starting an investigation into drug companies including Roche Holding AG, Pfizer Inc. and Aspen Pharmacare Holdings Ltd. for allegedly charging excessive prices.

Roche and Pfizer are suspected of charging high prices for breast and lung-cancer drugs respectively while Aspen may have abused its dominance in the market for bone and blood cancer drugs, the country’s Competition Commission said on Tuesday.

“The matter is of grave national importance,” the antitrust body said in a statement.

South Africa’s investigation follows probes by the European Union last month into pharmaceutical companies including Aspen for the pricing of cancer drugs. The EU move was prompted by action in the U.K. and Italy. Separately, U.S. officials have been looking at pricing of generic medicines for more than two years, triggering civil lawsuits from customers who say they were overcharged.

A 12-month course of Roche’s trastuzumab breast cancer medicine, branded Herceptin and Herclon, costs about 500,000 rand ($39,000) if administered privately, while is offered at “substantially lower prices” in the public sector, the commission said.

“As a result of exorbitant prices, most breast cancer patients in both the private and public sectors are unable to get treatment,” it said. The investigation related to Aspen is into its generic products, and similar to the EU’s probe.

Aspen hasn’t increased prices outside of a framework established by South Africa’s Department of Health and is “committed to full and constructive engagement” with the commission’s investigation, the Durban-based company said in a statement.

Roche will provide all required information once it is notified of the probe, spokesperson Aadila Fakier said by email. Pfizer didn’t immediately respond to requests for comment.

To contact the reporters on this story: Arabile Gumede in Johannesburg at agumede@bloomberg.net, Loni Prinsloo in Johannesburg at lprinsloo3@bloomberg.net, Kevin Crowley in Johannesburg at kcrowley1@bloomberg.net.

To contact the editors responsible for this story: Lynn Thomasson at lthomasson@bloomberg.net, Gordon Bell, Alastair Reed

©2017 Bloomberg L.P.

Bloomberg